GET DAILY SIGNALSQuantum-Si (QSI) Shares Advance +37% on Proteus Milestones
Key Takeaways
- QSI shares climbed roughly 37% over the trailing 30 days, rising from a close near $1.07 in late September to about $1.47 in late October.
- The move was driven primarily by development milestones for its next-generation Proteus single-molecule protein sequencing platform.
- Quantum-Si regained compliance with Nasdaq's $1.00 minimum-bid-price requirement after the stock closed above that threshold for 10 consecutive sessions.
- The company remains a pre-revenue, pre-profit development story: revenue totaled $344,000 in the second quarter of 2026, with significant operating losses.
- Management has shifted the anticipated commercial launch of Proteus to the second quarter of 2027, a key timeline investors continue to monitor.
- H.C. Wainwright reiterated a Buy rating and a $4.00 price target on the shares following the Proteus data releases.
Quantum-Si (QSI) Company Overview and Market Position
Quantum-Si Incorporated is a life sciences technology company focused on proteomics, the study of the full set of proteins expressed within a cell. The company has developed a proprietary, semiconductor-chip-based single-molecule detection platform that enables next-generation protein sequencing, an approach designed to read proteins in a massively parallel fashion rather than one at a time. Its commercial product line includes the Platinum and Platinum Pro benchtop sequencers, the Platinum Analysis Software, and associated consumable kits.
Quantum-Si's core thesis is that its technology can deliver faster, lower-cost, and more informative protein analysis than legacy mass spectrometry workflows, which are often expensive and complex. Investors follow the stock primarily for its development pipeline, led by the Proteus platform, which is intended to provide meaningfully higher sequencing output, greater sample throughput, and automated analysis relative to the current Platinum Pro system. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Quantum-Si (QSI) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, QSI shares advanced approximately 37%, moving from a closing price near $1.07 in late September to roughly $1.47 in late October. The rally was punctuated by sharp single-day gains on elevated volume, including a session in which trading volume reached roughly seven times the stock's 100-day average.
The move extended a broader recovery. For much of the summer, QSI traded below the $1.00 Nasdaq minimum-bid threshold, and shares were near $0.80 as recently as late August. The stock then more than doubled off those late-summer levels, reflecting renewed confidence in the Proteus development timeline and the company's regained exchange compliance. Despite the strong advance, the shares remain well below their 52-week high near $2.73.
What Drove QSI Stock Price in the Last 30 Days
The primary catalyst was a sequence of Proteus development updates. In late September, Quantum-Si presented interim data at the 2026 World HUPO Congress showing that Proteus delivered a median of roughly 30 times more sequencing alignments per chamber than Platinum Pro, a 4.8-times-lower median false discovery rate, and detection of cysteine and histidine residues that Platinum Pro could not identify. The announcement triggered a gain of more than 20% in a single session.
The momentum continued in October when the company disclosed that Proteus could now detect 19 of the 20 standard amino acids, up from 18 demonstrated earlier, and reaffirmed its expectation of detecting all 20 by the end of 2026. Shares jumped again on that news. The rally also coincided with Quantum-Si's confirmation in mid-October that it had regained Nasdaq minimum-bid-price compliance, removing a listing-related overhang that had pressured sentiment since a July deficiency notice. Founder Jonathan Rothberg publicly promoted the milestones, and H.C. Wainwright reiterated its Buy rating and $4.00 price target.
What Drove QSI Stock Performance Over the Last Quarter
The broader quarterly trend reflects a shift in investor focus from near-term financials to the Proteus commercialization roadmap. Earlier in 2026, Quantum-Si postponed Proteus's launch to the second quarter of 2027 and announced a roughly 20% workforce reduction expected to generate about $12 million in annualized operating expense savings. Those moves weighed on sentiment while the stock lingered below $1.00.
Subsequent development milestones reversed the narrative. Management reported that sequencing runs on multiple Proteus prototype systems were already meeting or exceeding Platinum Pro performance, and the company pointed to a substantial non-human proteomics market opportunity, including applications in agriculture, pathogen detection, and gene therapy. The regained Nasdaq compliance, combined with a rebound in speculative interest in single-molecule and AI-enabled life sciences tools, supported a sustained recovery into late October.
QSI Stock Forecast Drivers: What Investors Should Watch Next
The next major checkpoint is Quantum-Si's third-quarter 2026 financial results and business update, scheduled for early November, where management is expected to address Proteus development progress, cash runway, and the timeline for detecting all 20 amino acids. Investors should also monitor whether the company can hold its regained Nasdaq compliance and whether additional capital raises create dilution. Beyond the near term, the key variables are the completion of the all-20 amino acid demonstration, Proteus manufacturing readiness, and the commercial launch targeted for the second quarter of 2027. Because revenue remains minimal and the business is still loss-making, execution risk, cash consumption, and competitive dynamics in the proteomics tools market remain the central considerations for the stock's outlook. From what I see, this is important because the timeline for Proteus will likely dictate near-term sentiment.
Using Tickeron’s AI Tools for Deeper Analysis
In my research process, I frequently review Tickeron’s Trending AI Robots to compare how automated strategies are positioned on development-stage names like this one. The platform highlights top-performing bots across different styles and timeframes, which helps put price action into a broader algorithmic context without replacing fundamental work. It is one practical way to see data-driven signals alongside the milestones discussed above.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
QSI's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for QSI turned positive on October 27, 2026. Looking at past instances where QSI's MACD turned positive, the stock continued to rise in 37 of 43 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on QSI as a result. In 80 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
QSI moved above its 50-day moving average on September 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for QSI crossed bullishly above the 50-day moving average on September 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
The 50-day moving average for QSI moved above the 200-day moving average on October 23, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +6.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where QSI advanced for three days, in 157 of 196 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
The Aroon Indicator entered an Uptrend today. In 94 of 122 cases where QSI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
QSI broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.126) is normal, around the industry mean (3.870). P/E Ratio (-3.804) is within average values for comparable stocks, (1.382). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (100.000) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. QSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement